KUMAMOTO University

R

研究業績RESEARCH ACHIEVEMENTS

  1. Yamada R, Arima K, Yano H, Fujiwara Y, Yamashita K, Kanemitsu K, Hanada N, Yasunaga JI, Iwatsuki M, Mikami Y, Komohara Y.

    Impact of HTLV-1 infection on clinicopathological characteristics and tumour immune microenvironment in colorectal cancer.

    Virchows Arch doi: 10.1007/s00428-025-04074-w.

    https://pubmed.ncbi.nlm.nih.gov/40111448/

  2. Kidiga M, Murata M, Grover P, Ode H, Iwatani Y, Seki Y, Kuramitsu M, Morimoto M, Natsume T, Kaneko A, Hayashi S, Yasunaga JI, Matsuoka M, Mizukami T, Akari H.

    Identification of occult STLV-1 infection in Japanese macaques.

     J Infect Dis 5:jiaf120,2025.doi: 10.1093/infdis/jiaf120.

     

  3. Shichijo T, Yasunaga JI.

    Stratagems of HTLV-1 for persistent infection and the resultant oncogenesis: Immune evasion and clonal expansion.

    Leuk Res 16:152:107680,2025.doi: 10.1016/j.leukres.2025.107680.

    https://pubmed.ncbi.nlm.nih.gov/40120237/

  4. Liu B, Yasunaga JI, Liang Y, Zhou R, Yang S, Yuan X, Liu J, Zuo X, Miura M, Higuchi Y, Matsumoto T, Toyoda K, Matsuoka M, Ma G.

    Identification of AK4 and RHOC as potential oncogenes addicted by adult T cell leukemia.

    Proc Natl Acad Sci U S A 25;122(8):e2416412122,2025.doi: 10.1073/pnas.2416412122.

  5. Grover P, Murata M, Kidiga M, Hayashi S, Ode H, Iwatani Y, Morimoto M, Natsume T, Kaneko A, Yasunaga JI, Matsuoka M, Kuramitsu M, Seki Y, Mizukami T, Akari H.

    Identification of natural remission of mother-to-child retroviral transmission.

    J Infect Dis 4:jiaf064,2025.doi: 10.1093/infdis/jiaf064. Online ahead of print.

  6. Hayakawa M, Seki Y, Ikezoe T, Yamakawa K, Okamoto K, Kushimoto S, Sakamoto Y, Itagaki Y, Takahashi Y, Ishikura H, Mayumi T, Tamura T, Nishio K, Kawazoe Y, Shigeno A, Takatani Y, Tampo A, Nakamura Y, Mochizuki K, Yada N, Kawasaki K, Kiyokawa A, Morikawa M, Uchiba M, Matsumoto T, Asakura H, Madoiwa S, Uchiyama T, Yamada S, Koga S, Ito T, Iba T, Kawano N, Gando S, Wada H; Committee of the Clinical Practice Guidelines for Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis, Hemostasis.

    Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: part 4-trauma, burn, obstetrics, acute pancreatitis/liver failure, and others.

    Int J Hematol May;121(5):633-652,2025.doi: 10.1007/s12185-025-03918-0.

    https://pubmed.ncbi.nlm.nih.gov/39890756/

     

     

  7. Seki Y, Okamoto K, Ikezoe T, Yamakawa K, Madoiwa S, Uchiyama T, Asakura H, Yamada S, Koga S, Ishikura H, Ito T, Iba T, Uchiba M, Kawasaki K, Kawano N, Gando S, Kushimoto S, Sakamoto Y, Tamura T, Nishio K, Hayakawa M, Matsumoto T, Mayumi T, Wada H; Committee of the Clinical Practice Guidelines for Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis and Hemostasis.

    Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities.

    Int J Hematol May;121(5):622-632,2025.doi: 10.1007/s12185-024-03912-y.

    https://pubmed.ncbi.nlm.nih.gov/39792236/

  8. Tanaka A, Ishitsuka Y, Ohta H, Takenouchi N, Nakagawa M, Koh KR, Onishi C, Tanaka H, Fujimoto A, Yasunaga JI, Matsuoka M.

    Integrative analysis of ATAC-seq and RNA-seq for cells infected by human T-cell leukemia virus type 1.

    PLoS Comput Biol 2;21(1):e1012690,2025.doi: 10.1371/journal.pcbi.1012690.

    https://pubmed.ncbi.nlm.nih.gov/39746113/

  9. Yamamura A, Nosaka K, Tatetsu H, Yasunaga JI.

    Successful treatment with EPOCH followed by mogamulizumab for angioimmunoblastic T-cell lymphoma with myelofibrosis and pure red cell aplasia.

    Rinsho Ketsueki 66(1):24-29,2025.doi: 10.11406/rinketsu.66.24.

  10. Yamakawa K, Okamoto K, Seki Y, Ikezoe T, Ito T, Iba T, Gando S, Ushio N, Totoki T, Wada T, Asakura H, Ishikura H, Uchiba M, Uchiyama T, Kawasaki K, Kawano N, Kushimoto S, Koga S, Sakamoto Y, Tamura T, Nishio K, Hayakawa M, Matsumoto T, Madoiwa S, Mayumi T, Yamada S, Wada H; Committee of the Clinical Practice Guidelines for Management of Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis and Hemostasis.

    Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis.

    Int J Hematol 16,2024.doi: 10.1007/s12185-024-03896-9.

  11. Utsunomiya A, Yasunaga JI, Tabuchi T, Nakano N, Odawara J, Kubota A, Tokunaga M, Miyazono T, Matsuoka M, Ito Y, Tashiro Y.

    A 25-year clonal resurrection in adult T-cell leukemia-lymphoma relapse.

    Int J Hematol 121(3):416-420,2024.doi: 10.1007/s12185-024-03901-1.

    https://pubmed.ncbi.nlm.nih.gov/39719504/

  12. Yamamoto T, Furukawa A, Zhou Y, Kono N, Kitajima S, Ohguchi H, Kawano Y, Ito S, Araki N, Ohtsuki S, Masuda T.

    Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells.

    iScience  15;27(12):111399,2024.doi: 10.1016/j.isci.2024.111399.

    https://pubmed.ncbi.nlm.nih.gov/39687025/

  13. Kawano N, Ikezoe T, Seki Y, Yamakawa K, Okamoto K, Fukatsu M, Madoiwa S, Uchiyama T, Asakura H, Yamada S, Koga S, Ishikura H, Ito T, Iba T, Uchiba M, Kawasaki K, Gando S, Kushimoto S, Sakamoto Y, Tamura T, Nishio K, Hayakawa M, Matsumoto T, Mayumi T, Wada H; Committee of the Clinical Practice Guidelines for Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis and Hemostasis.

    Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 2: hematologic malignancy.

     Int J Hematol 121(5):605-621,2024.doi: 10.1007/s12185-024-03887-w.

    https://pubmed.ncbi.nlm.nih.gov/39674834/

  14. Morikawa K, Izumiya Y, Takashio S, Kawano Y, Oguni T, Kuyama, N, Oike F, Yamamoto M, Tabata N, Ishii M, Hanatani S, Hoshiyama T, Kanazawa H, Matsuzawa Y, Usuku H, Yamamoto E, Ueda M, Tsujita K.

    Early experience with daratumumab-containing regimens in patients with light-chain cardiac amyloidosis.

    Journal of Cardiology 3:S0914-5087(24)00216-8,2024.doi: 10.1016/j.jjcc.2024.11.003.

    https://pubmed.ncbi.nlm.nih.gov/39577830/

  15. Maruyama D, Jacobsen E, Porcu P, Allen P, Ishitsuka K, Kusumoto S, Narita T, Tobinai K, Foss F, Tsukasaki K, Feldman T, Imaizumi Y, Izutsu K, Morishima S, Yamauchi N, Yuda J, Brammer JE, Kawamata T, Ruan J, Nosaka K, Utsunomiya A, Wang J, Zain J, Kakurai Y, Yamauchi H, Hizukuri Y, Biserna N, Tachibana M, Inoue A, Horwitz SM.

    Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.

    Lancet Oncol 25(12):1589-1601,2024.doi: 10.1016/S1470-2045(24)00502-3.

  16. Oda K, Hayashi H, Yamamoto K, Kondo S, Katanoda T, Okamoto S, Miyakawa T, Iwanaga E, Nosaka K, Kawaguchi T, Nakata H.

    Antibiotic spectrum coverage scoring as a potential metric for evaluating the antimicrobial stewardship team activity: a single-center study.

    Infect Control Hosp Epidemiol 10;45(11):1-9,2024.doi: 10.1017/ice.2024.137.

    https://pubmed.ncbi.nlm.nih.gov/39387201/

  17. Oda K, Okamoto S, Iwanaga E, Nakata H.

    Investigating the WHO’s AWaRe classification for assessing antimicrobial stewardship programs: A single-center study.

    J Infect Chemother 31(1):102511,2024.doi: 10.1016/j.jiac.2024.08.025.

    https://pubmed.ncbi.nlm.nih.gov/39233122/

  18. Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Abe M, Hojo S, Nakanishi T, Rai S.

    Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.

    Int J Hematol 120(5):621-630,2024.doi: 10.1007/s12185-024-03834-9.

    https://pubmed.ncbi.nlm.nih.gov/39179948/

  19. Kusumoto S, Munakata W, Machida R, Terauchi T, Onaya H, Oguchi M, Iida S, Nosaka K, Suzuki Y, Harada Y, Miyazaki K, Maruta M, Fukuhara N, Toubai T, Kubota N, Ohmachi K, Saito T, Rai S, Mizuno I, Fukuhara S, Takeuchi M, Tateishi U, Maruyama D, Tsukasaki K, Nagai H.

    Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305).

    Cancer Sci. 115(10):3384-3393,2024.doi: 10.1111/cas.16281.

    https://pubmed.ncbi.nlm.nih.gov/39034771/

     

  20. Nakamura T, Yoshinouchi T, Okumura M, Yokoyama T, Mori D, Nakata H, Yasunaga JI, Tanaka Y.

    Diverse antifungal potency of terbinafine as a therapeutic agent against Exophiala dermatitidis in vitro.

    Sci Rep 11;14(1):27500,2024.doi: 10.1038/s41598-024-78815-3.

  21. Usuku H, Yamamoto E, Sakata K, Hirata S, Toda A, Oike F, Tabata N, Ishii M, Hanatani S, Hoshiyama T, Sueta D, Kanazawa H, Arima Y, Takashio S, Matsuzawa Y, Kawano H, Yasunaga JI, Tsujita K.

    Usefulness of platelet count to predict concomitant valvular heart disease in patients with systemic lupus erythematosus.

    Int J Cardiol Heart Vasc 24:53:101420,2024.doi: 10.1016/j.ijcha.2024.101420. eCollection 2024 Aug.

    https://pubmed.ncbi.nlm.nih.gov/38826833/

  22. Kawano Y, Nishimura N, Yasunaga JI.

    Serum monoclonal immunoglobulin light chain detection differs between immunofixation electrophoresis methods in patients with AL amyloidosis.

    International Journal of Hematology  120(2):212-216,2024.doi: 10.1007/s12185-024-03790-4.

     

  23. Mitani K, Lee JW, Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Murotani K, Shimizu M, Matsuda A, Ozawa K, Nakao S.

    Long-term efficacy and safety of romiplostim in refractory aplastic anemia: Follow-up of a phase II/III study.

    Blood Adv 26;8(6):1415-1419,2024.doi: 10.1182/bloodadvances.2023010959.

  24. Kaneko K, Suto M, Miyagawa E, Mikami M, Nakamura Y, Murashima A, Takehara K.

    Preconception underweight impact on postnatal osteoporotic fracture: a retrospective cohort study using Japanese claims data.

    BMC Pregnancy Childbirth 25;24(1):315,2024.doi: 10.1186/s12884-024-06514-y.

    https://pubmed.ncbi.nlm.nih.gov/38664710/

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo*kumamoto-u.ac.jp
    (*はアットマーク)
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.